Blocking blood vessel formation prevents brain tumor recurrence in mice

February 22, 2010

Patients with glioblastoma multiforme (GBM), an extremely aggressive brain tumor, have a very poor prognosis. Despite high dose radiotherapy, 75% of patients die within two years, usually as a result of tumor recurrence within the irradiation field. Martin Brown and colleagues, at Stanford University School of Medicine, have now provided insight into the mechanism of such recurrence by studying a mouse model of GBM in which a human GBM cell line was grafted into the brain of mice, thus highlighting potential new therapeutic approaches to the treatment of GBM.

Formation of new is an essential component of tumor recurrence. In the study, the authors found that in their GBM model, irradiation induced recruitment to the tumor site of cells able to facilitate blood vessel formation by a process known as vasculogenesis. Further analysis indicated that these cells were recruited by the soluble molecule SDF-1, which bound to the protein CXCR4 on the surface of the recruited cells. Importantly, disrupting the SDF-1/CXCR4 interaction prevented the recruitment of vasculogenic cells to the tumor site and thereby blocked postirradiation development of functional tumor vasculature, resulting in abrogation of tumor regrowth. The authors suggest that these data might be readily applicable to the clinic because a small molecule inhibitor of SDF-1/CXCR4 interactions is already clinically approved to obtain for transplantation.

In an accompanying commentary, Jeffrey Greenfield and David Lyden, at Weill Cornell Medical College, New York, discuss the importance of the study by Brown and colleagues and suggest that treatment for GMB should be tailored to target the specific blood vessel forming pathway operational at a given stage of disease.

More information: View this article at: www.jci.org/articles/view/4028 … a33226968525f5711bde

Related Stories

Recommended for you

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.